The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting the successful pivot toward profitability within the cannabis sector, Aurora Cannabis reported record financial results for the fourth quarter and full fiscal year 2026. According to reports, the company achieved record annual global medical cannabis net revenue of $288.6 million, representing an 18% year-over-year increase driven by international expansion. Furthermore, the company delivered record annual Adjusted EBITDA of $53.8 million, marking a significant 32% growth compared to the previous year.
This outperformance comes as industry peers like Canopy Growth and Tilray struggle to balance margins amid inflationary pressures, with Aurora now standing out due to its robust balance sheet featuring $164.7 million in cash and zero debt. Per market data, the company's production capacity was further bolstered by the acquisition of Safari Flower Company in April 2026 to serve international markets. In related sector news, American Outdoor Brands (AOUT) is scheduled to release its earnings on June 25, 2026, keeping the broader consumer-health space in focus.
Sign in to access this content
Sign InFrom an operational standpoint, traders should monitor the sustainability of positive cash flow as the stock reacts to these milestone figures. Looking at the economic calendar, Canadian markets remain sensitive to Governor Bailey's upcoming commentary and the recent unemployment data of 6.6% (as of June 5, 2026). The company's ability to leverage its debt-free status for further international scaling will be the primary catalyst for the stock in upcoming sessions.